Advertisement
HRTX vs TENX
Which Stock Would AI Choose? Heron Therapeutics (HRTX) vs. Tenax Therapeutics (TENX) Stock Comparison
Key Takeaways
- HRTX (Heron Therapeutics) is a commercial-stage biotechnology company with roughly $151 million in trailing-twelve-month revenue, while TENX (Tenax Therapeutics) is a development-stage biotech that does not yet generate product revenue.
- Both stocks have faced sharp sentiment shifts in recent weeks, driven by very different catalysts: a patent ruling for HRTX and a failed pivotal clinical trial for TENX.
- Heron Therapeutics withdrew its 2026 financial guidance and said it is evaluating strategic alternatives after an adverse patent decision involving its CINVANTI antiemetic product.
- Tenax Therapeutics saw its shares fall roughly 90% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
- Analyst actions have diverged in severity: HRTX received a downgrade to Neutral, while TENX faced multiple downgrades, large price-target cuts, and a securities class-action filing.
- Relative performance favors neither name cleanly, but HRTX offers a revenue base and diversified product portfolio, whereas TENX is now a more binary, cash-burn clinical story.
- For more detail on each name, explore the HRTX Major News and HRTX Today's Price Move pages, as well as the TENX Major News and TENX Today's Price Move pages.
- To see how automated strategies are currently positioning across these and other tickers, explore the Trending AI Robots page.
Introduction
This stock comparison places two small-cap biotechnology companies side by side for traders and investors evaluating risk across very different stages of drug development. HRTX represents a revenue-generating commercial player in acute care and oncology, while TENX reflects the high-risk profile of a clinical-stage cardiopulmonary company. Recent market activity has repriced both names substantially, making their relative performance and market positioning a useful case study in how catalysts, balance sheets, and pipeline risk can diverge within the same sector.
HRTX Overview and Recent Performance
Heron Therapeutics is a commercial-stage biotechnology company developing and selling products for acute care and oncology patients. Its portfolio includes ZYNRELEF, an extended-release local anesthetic; APONVIE, an intravenous treatment for postoperative nausea and vomiting; and the antiemetics CINVANTI and SUSTOL, which help prevent chemotherapy-induced nausea.
In recent weeks, HRTX has been pressured by an adverse court ruling related to CINVANTI patents. Following that decision, the company withdrew its full-year 2026 guidance, citing uncertainty around potential generic competition for its largest-selling product, and said it is tightening spending while evaluating strategic alternatives. Analysts responded with a downgrade to Neutral from Buy. Despite this, the company's acute care franchise has shown growth, and its trailing-twelve-month revenue remains above $150 million. The stock trades well below its 52-week highs, reflecting heightened uncertainty rather than a collapse in the underlying commercial business.
TENX Overview and Recent Performance
Tenax Therapeutics is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies, including oral levosimendan (TNX-103) for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company does not yet generate product revenue and relies on its cash position to fund ongoing clinical programs.
Recent market activity for TENX has been dominated by the August 2026 announcement that its Phase 3 LEVEL trial of TNX-103 did not meet its primary endpoint or a key secondary endpoint. The stock fell approximately 90% on the news, prompting several analysts to downgrade ratings and sharply reduce price targets, while a securities class-action complaint was subsequently filed. Some research desks continue to see potential in subgroups of sicker patients, and certain analysts have maintained Buy or Outperform ratings at much lower targets. The stock remains well below prior highs as investors weigh remaining clinical options against financing and execution questions.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, yet only a select group earns a place in its curated Trending AI Robots section. This collection is designed to surface the strategies best suited to current market conditions, rather than the entire catalog. The bots vary considerably in trading style, strategy, timeframe, performance, and the set of tickers they follow, so a single bot is never one-size-fits-all. For traders interested in how algorithmic approaches are currently reading names such as HRTX and TENX, reviewing the Trending AI Robots page can offer a data-driven complement to fundamental research.
Head-to-Head Comparison
The most important contrast between these two companies is stage and revenue. HRTX has a diversified, commercially approved product portfolio and a revenue base measured in the hundreds of millions annually, but its near-term outlook is clouded by patent litigation and a potential generic threat to its top product. TENX is a pure pipeline bet whose lead asset has already failed a pivotal trial, leaving the company exposed to financing risk and a narrower set of future catalysts.
On growth drivers, Heron's acute care franchise (ZYNRELEF and APONVIE) has posted year-over-year gains and benefits from improving reimbursement, while its oncology segment faces competitive and legal headwinds. Tenax's remaining value hinges on whether future studies can demonstrate benefit in more severely ill PH-HFpEF patients, an inherently uncertain proposition. Risk profiles also differ: HRTX carries execution and legal risk against a stable commercial foundation, whereas TENX carries binary clinical risk, higher cash-burn sensitivity, and litigation overhang. Market sentiment is cautious toward both, but the repricing in TENX has been far more extreme.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue stability, and the relative breadth of near-term catalysts, Tickeron's AI would likely favor HRTX over TENX in the current environment. Heron's commercial revenue, multiple approved products, and a more defined path to either resolution or strategic alternatives provide a comparatively more stable footing than Tenax's post-trial, cash-burn-heavy clinical story. That said, the verdict is probabilistic rather than definitive: HRTX still faces meaningful patent uncertainty, and a favorable development in Tenax's subpopulation strategy could shift relative positioning. Traders should treat the comparison as a snapshot of current risk and momentum, not a fixed outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRTX is a Hold and TENX is a Hold.
Momentum Indicator for HRTX turns negative, indicating new downward trend
HRTX saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 73 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HRTX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
HRTX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
HRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 141 cases where HRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TENX in -11.41% downward trend, sliding for three consecutive days on November 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TENX declined for three days, in 311 of 358 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 37 cases where TENX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 79 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TENX's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +2.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.498). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HRTX | TENX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 89 | 92 | |
P/E GROWTH RATING 1..100 | 13 | 98 | |
SEASONALITY SCORE 1..100 | 26 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TENX's Valuation (38) in the Medical Specialties industry is somewhat better than the same rating for HRTX (78) in the Biotechnology industry. This means that TENX’s stock grew somewhat faster than HRTX’s over the last 12 months.
TENX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HRTX (100) in the Biotechnology industry. This means that TENX’s stock grew similarly to HRTX’s over the last 12 months.
TENX's SMR Rating (98) in the Medical Specialties industry is in the same range as HRTX (100) in the Biotechnology industry. This means that TENX’s stock grew similarly to HRTX’s over the last 12 months.
HRTX's Price Growth Rating (89) in the Biotechnology industry is in the same range as TENX (92) in the Medical Specialties industry. This means that HRTX’s stock grew similarly to TENX’s over the last 12 months.
HRTX's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for TENX (98) in the Medical Specialties industry. This means that HRTX’s stock grew significantly faster than TENX’s over the last 12 months.
| HRTX | TENX | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 79% |
| Stochastic ODDS (%) | 4 days ago 83% | 4 days ago 81% |
| Momentum ODDS (%) | 4 days ago 90% | 4 days ago 87% |
| MACD ODDS (%) | 4 days ago 82% | N/A |
| TrendWeek ODDS (%) | 4 days ago 83% | 4 days ago 88% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 88% |
| Advances ODDS (%) | 13 days ago 84% | 7 days ago 82% |
| Declines ODDS (%) | 11 days ago 89% | 5 days ago 87% |
| BollingerBands ODDS (%) | 4 days ago 80% | 4 days ago 90% |
| Aroon ODDS (%) | 4 days ago 77% | 4 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HRTX’s FA Score shows that 1 FA rating(s) are green while TENX’s FA Score has 0 green FA rating(s).
- HRTX’s FA Score: 1 green, 4 red.
- TENX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HRTX’s TA Score shows that 4 TA indicator(s) are bullish while TENX’s TA Score has 3 bullish TA indicator(s).
- HRTX’s TA Score: 4 bullish, 5 bearish.
- TENX’s TA Score: 3 bullish, 5 bearish.
Price Growth
HRTX (@Biotechnology) experienced а +5.51% price change this week, while TENX (@Biotechnology) price change was -5.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
HRTX is expected to report earnings on Nov 09, 2026.
TENX is expected to report earnings on Apr 01, 2027.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
HRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with FULC. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To HRTX | 1D Price Change % | ||
|---|---|---|---|---|
| HRTX | 100% | +4.64% | ||
| FULC - HRTX | 49% Loosely correlated | +0.54% | ||
| ABVX - HRTX | 45% Loosely correlated | +1.85% | ||
| AMRN - HRTX | 44% Loosely correlated | +0.30% | ||
| SION - HRTX | 41% Loosely correlated | N/A | ||
| TENX - HRTX | 40% Loosely correlated | +3.68% | ||
More | ||||
TENX and
Correlation & Price change
A.I.dvisor indicates that over the last year, TENX has been closely correlated with SION. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if TENX jumps, then SION could also see price increases.
| Ticker / NAME | Correlation To TENX | 1D Price Change % | ||
|---|---|---|---|---|
| TENX | 100% | +3.68% | ||
| SION - TENX | 93% Closely correlated | N/A | ||
| AVXL - TENX | 47% Loosely correlated | +3.60% | ||
| CORT - TENX | 41% Loosely correlated | +1.59% | ||
| HRTX - TENX | 40% Loosely correlated | +4.64% | ||
| MGNX - TENX | 32% Poorly correlated | +4.95% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NGHT | 21.00 | 0.81 | +4.00% |
| Nicholas Bitcoin and Treasuries AfterDark ETF (NGHT) | |||
| PDP | 124.86 | 1.30 | +1.06% |
| Invesco Dorsey Wright Momentum ETF (PDP) | |||
| KLIP | 21.72 | 0.07 | +0.32% |
| KraneShares KWEB Covered Call Strategy ETF (KLIP) | |||
| GQI | 58.29 | -0.20 | -0.33% |
| Natixis Gateway Quality Income ETF (GQI) | |||
| TTXD | 15.19 | -0.27 | -1.78% |
| Direxion Daily Technology Top 5 Bear 2X ETF (TTXD) | |||